Evidence map›Paper›PMID 40919115›Full record

ArticleClinical and translational radiation oncology2025

Prognostic factors, patterns of failure and re-irradiation in hypofractionated stereotactic radiotherapy-treated brain metastases from non-small cell lung cancer.

Dayu Xu, Yechun Pang, Jinghan Qu, Jiuang Mao, Tiantian Guo, Shanshan Jiang, Yue Zhou, Li Chu, Xi Yang, Xiao Chu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dayu XuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yechun PangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jinghan QuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jiuang MaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Tiantian GuoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shanshan JiangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yue ZhouDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Li ChuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xi YangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiao ChuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shengping WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200030, China.
Tong TongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200030, China.
Zhengfei ZhuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jianjiao NiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hypofractionated stereotactic radiotherapy (fSRT) is increasingly used for brain metastases (BMs) from non-small cell lung cancer (NSCLC). However, relevant data concerning treatment outcomes of fSRT and clinical utility of re-irradiation using fSRT (re-fSRT) remain scarce. Methods: Consecutive NSCLC patients with fSRT-treated BMs from May 2018 to May 2022 were included. The cumulative incidence of intracranial local recurrence (iLR), intracranial progressive disease (iPD) and symptomatic radiation necrosis (sRN) were calculated from the initiation of fSRT, choosing death as the competing event. Patients with limited iPD (number ≤5 and size ≤3 cm) and without iLR developed within 12 months, were classified as re-fSRT candidates. The clinical value of re-fSRT and dosimetric predictors of sRN were investigated. Results: With a median follow-up of 22.3 months, the 1-year, 2-year and 3-year cumulative incidence of iLR among the 218 identified patients were 8.1 %, 12.3 %, 17.8 %, respectively. Biological effective dose, total tumor volume and concurrent systemic therapy were associated with the risk of iLR. Notably, 45 (76.3 %) of the 59 patients with iPD were feasible for re-fSRT. Re-fSRT was performed in 19 (42.2 %) of the 45 candidates and associated with improved survival ( Conclusion: fSRT is a promising treatment for limited BMs from NSCLC and some patients may benefit from re-fSRT.

Indexed as

Brain metastasisfSRTNon-small cell lung cancerRe-fSRT

Identifiers

PMID40919115
PMCPMC12409328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.